Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases.

Gampa G, Kim M, Mohammad AS, Parrish KE, Mladek AC, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2019 Jan 8. pii: jpet.118.253708. doi: 10.1124/jpet.118.253708. [Epub ahead of print]

2.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

3.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Sep;17(9):1893-1901. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.

PMID:
29970480
4.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

5.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28.

6.

Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM, Maran A, Galindo M, van Wijnen AJ, Sarkaria JN, Yaszemski MJ.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313. doi: 10.1016/j.bbrc.2017.03.033. Epub 2017 Mar 12.

7.

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, Nair AA, Lee JH, Yan H, Decker PA, Zhang Z, Sarkaria JN.

Cell Rep. 2016 Mar 22;14(11):2587-98. doi: 10.1016/j.celrep.2016.02.045. Epub 2016 Mar 10.

8.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

9.

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

Ramirez YP, Mladek AC, Phillips RM, Gynther M, Rautio J, Ross AH, Wheelhouse RT, Sakaria JN.

Mol Cancer Ther. 2015 Jan;14(1):111-9. doi: 10.1158/1535-7163.MCT-14-0113. Epub 2014 Oct 28.

10.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

11.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

12.

ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.

Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, Sarkaria JN.

J Neurooncol. 2012 Dec;110(3):349-57. doi: 10.1007/s11060-012-0979-0. Epub 2012 Oct 3.

13.

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN.

Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.

14.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

15.

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026.

16.

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.

Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN.

Mol Cancer Ther. 2009 Feb;8(2):407-14. doi: 10.1158/1535-7163.MCT-08-0854. Epub 2009 Jan 27.

17.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.

J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.

18.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.

Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152.

19.

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN.

Head Neck. 2008 Jun;30(6):790-9. doi: 10.1002/hed.20770.

20.

Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.

Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB.

J Thorac Oncol. 2007 Aug;2(8):751-7.

21.
22.

The first initiative targeted to increase the training of African-American scientists in pancreatic cancer research: the Mayo Clinic College of Medicine-Oakwood College alliance.

Randriamahefa A, Fernandez-Zapico ME, Mladek AC, Evans L, Melbourne L, Osborne S, Cochran RL, Knight M, Beckford D, Gullo S, Paul A, McGee R, Urrutia R.

Pancreas. 2005 Apr;30(3):288-91. No abstract available.

PMID:
15782110
23.

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN.

Cancer Res. 2002 Dec 15;62(24):7291-7.

Supplemental Content

Loading ...
Support Center